The INDIGO trial for vorasidenib used "time to next intervention" as a key secondary endpoint. This patient-centric metric values delaying more toxic treatments like radiation and chemotherapy, thereby preserving neurocognitive function and quality of life, not just measuring tumor progression.
The success of the IDH inhibitor vorasidenib in glioma was driven by its specific design for blood-brain barrier (BBB) penetration. This contrasts with its predecessor, which failed in brain tumors due to poor CNS penetration, highlighting that BBB is a critical design consideration for neuro-oncology drugs.
The pan-RAF inhibitor tovorafenib causes a significant, but reversible, decrease in growth velocity in children. This is not due to endocrinopathy but direct C-RAF inhibition slowing growth plate maturation. Growth resumes and "catches up" after therapy cessation, a critical counseling point for families.
Unlike most cancers, National Comprehensive Cancer Network (NCCN) guidelines recommend clinical trials as the preferred first-line treatment for glioblastoma patients with good performance status. This rare recommendation highlights the dismal outcomes with existing therapies and the urgent need for therapeutic innovation.
For pediatric low-grade gliomas, carboplatin and vincristine became the standard of care over the more effective TPCV regimen. This decision highlights the critical trade-off in pediatric oncology, where managing toxicity and long-term side effects in children can outweigh achieving maximum efficacy.
Beyond improving progression-free survival, the targeted therapy vorasidenib also provides a significant quality-of-life benefit by improving seizure control. Seizures are a common presenting symptom for low-grade glioma patients, and this added therapeutic effect makes the drug a more holistic treatment option.